Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-ABL1) value >10% at 3 months of therapy is statistically associated with poorer outcome, yet many of these patients still achieve satisfactory outcomes. We investigated 528 first-line imatinib-treated patients to...
Gespeichert in:
| Veröffentlicht in: | Blood 2014-07, Vol.124 (4), p.511-518 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 518 |
|---|---|
| container_issue | 4 |
| container_start_page | 511 |
| container_title | Blood |
| container_volume | 124 |
| creator | Branford, Susan Yeung, David T. Parker, Wendy T. Roberts, Nicola D. Purins, Leanne Braley, Jodi A. Altamura, Haley K. Yeoman, Alexandra L. Georgievski, Jasmina Jamison, Bronte A. Phillis, Stuart Donaldson, Zoe Leong, Mary Fletcher, Linda Seymour, John F. Grigg, Andrew P. Ross, David M. Hughes, Timothy P. |
| description | In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-ABL1) value >10% at 3 months of therapy is statistically associated with poorer outcome, yet many of these patients still achieve satisfactory outcomes. We investigated 528 first-line imatinib-treated patients to determine whether patients with the poorest outcome can be better discriminated at 3 months. All outcomes were significantly superior for the 410 patients with BCR-ABL1 ≤10% at 3 months (P < .001). However, the poorest outcomes among the 95 evaluable patients with BCR-ABL1 >10% at 3 months were identified by the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Patients with BCR-ABL1 halving time 10% at 3 months. The International Randomized IFN vs STI571 (IRIS) trial was registered at http://www.clinicaltrials.gov as #NCT00006343. The Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) trial was registered at http://www.clinicaltrials.gov as #NCT00124748. The Therapeutic Intensification in DE-novo Leukaemia (TIDEL) I trial was registered at http://www.ANZCTR.org.au as #ACTRN12607000614493. The TIDEL II trial was registered at http://www.ANZCTR.org.au as #ACTRN12607000325404.
•Among patients with >10% BCR-ABL1, at 3 months, the poorest-risk group can be distinguished by the rate of BCR-ABL1 decline from baseline.•Patients with BCR-ABL1 values on a constant downward trajectory may rapidly reach the level considered optimal with additional follow-up. |
| doi_str_mv | 10.1182/blood-2014-03-566323 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1548641049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120399328</els_id><sourcerecordid>1548641049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-defda0d0b2df127c51000a2fc2b1f9d326cb40c603d9cbee51c1d0143fbe34a63</originalsourceid><addsrcrecordid>eNp9kE1rVDEUhoModlr9B1KyEdyknnzc23s3hXawHzCiiK5DbnLipNxJpklG8d-bcdouXQVOnvcc3oeQdxzOOB_Ex2lOyTEBXDGQrOt7KeQLsuCdGBiAgJdkAQA9U-M5PyLHpdxDY6XoXpMjoYZulL1akPo1p58xlVCoT5luTQ0Ya6G_Q13T5ecVNdHRCw7v6dXyG7u8WnFqfMVMJd2kWNeFJk_DpsVimKjDLUbXZpHWNdJsKu7_n6MO7RwiviGvvJkLvn18T8iP60_fl7ds9eXmbnm5YlbBUJlD7ww4mITzXJzbjrdCRngrJu5HJ0VvJwW2B-lGOyF23HK37-gnlMr08oR8OOzd5vSww1L1JhSL82wipl3RvFNDrziosaHqgNqcSsno9Ta3WvmP5qD3vvU_33rvW4PUB98tdvp4YTdt0D2HngQ34OIAYOv5K2DWxTbDFl3IaKt2Kfz_wl_f8o9q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1548641049</pqid></control><display><type>article</type><title>Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Branford, Susan ; Yeung, David T. ; Parker, Wendy T. ; Roberts, Nicola D. ; Purins, Leanne ; Braley, Jodi A. ; Altamura, Haley K. ; Yeoman, Alexandra L. ; Georgievski, Jasmina ; Jamison, Bronte A. ; Phillis, Stuart ; Donaldson, Zoe ; Leong, Mary ; Fletcher, Linda ; Seymour, John F. ; Grigg, Andrew P. ; Ross, David M. ; Hughes, Timothy P.</creator><creatorcontrib>Branford, Susan ; Yeung, David T. ; Parker, Wendy T. ; Roberts, Nicola D. ; Purins, Leanne ; Braley, Jodi A. ; Altamura, Haley K. ; Yeoman, Alexandra L. ; Georgievski, Jasmina ; Jamison, Bronte A. ; Phillis, Stuart ; Donaldson, Zoe ; Leong, Mary ; Fletcher, Linda ; Seymour, John F. ; Grigg, Andrew P. ; Ross, David M. ; Hughes, Timothy P.</creatorcontrib><description>In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-ABL1) value >10% at 3 months of therapy is statistically associated with poorer outcome, yet many of these patients still achieve satisfactory outcomes. We investigated 528 first-line imatinib-treated patients to determine whether patients with the poorest outcome can be better discriminated at 3 months. All outcomes were significantly superior for the 410 patients with BCR-ABL1 ≤10% at 3 months (P < .001). However, the poorest outcomes among the 95 evaluable patients with BCR-ABL1 >10% at 3 months were identified by the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Patients with BCR-ABL1 halving time <76 days (n = 74) had significantly superior outcomes compared with patients whose BCR-ABL1 values did not halve by 76 days (n = 21; 4-year overall survival, 95% vs 58%, P = .0002; progression-free survival, 92% vs 63%, P = .008; failure-free survival, 59% vs 6%, P < .0001; and major molecular response, 54% vs 5%, P = .008). By multivariate analysis, the halving time was an independent predictor of outcome in this poor risk group. Our study highlighted that the rate of BCR-ABL1 decline may be a critical prognostic discriminator of the patients with very poor outcome among those >10% at 3 months. The International Randomized IFN vs STI571 (IRIS) trial was registered at http://www.clinicaltrials.gov as #NCT00006343. The Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) trial was registered at http://www.clinicaltrials.gov as #NCT00124748. The Therapeutic Intensification in DE-novo Leukaemia (TIDEL) I trial was registered at http://www.ANZCTR.org.au as #ACTRN12607000614493. The TIDEL II trial was registered at http://www.ANZCTR.org.au as #ACTRN12607000325404.
•Among patients with >10% BCR-ABL1, at 3 months, the poorest-risk group can be distinguished by the rate of BCR-ABL1 decline from baseline.•Patients with BCR-ABL1 values on a constant downward trajectory may rapidly reach the level considered optimal with additional follow-up.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2014-03-566323</identifier><identifier>PMID: 24859364</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antineoplastic Agents - therapeutic use ; Benzamides - therapeutic use ; Female ; Follow-Up Studies ; Fusion Proteins, bcr-abl - genetics ; Fusion Proteins, bcr-abl - metabolism ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality ; Male ; Middle Aged ; Piperazines - therapeutic use ; Prognosis ; Pyrimidines - therapeutic use ; Remission Induction ; Survival Rate ; Time Factors</subject><ispartof>Blood, 2014-07, Vol.124 (4), p.511-518</ispartof><rights>2014 American Society of Hematology</rights><rights>2014 by The American Society of Hematology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-defda0d0b2df127c51000a2fc2b1f9d326cb40c603d9cbee51c1d0143fbe34a63</citedby><cites>FETCH-LOGICAL-c408t-defda0d0b2df127c51000a2fc2b1f9d326cb40c603d9cbee51c1d0143fbe34a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24859364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Branford, Susan</creatorcontrib><creatorcontrib>Yeung, David T.</creatorcontrib><creatorcontrib>Parker, Wendy T.</creatorcontrib><creatorcontrib>Roberts, Nicola D.</creatorcontrib><creatorcontrib>Purins, Leanne</creatorcontrib><creatorcontrib>Braley, Jodi A.</creatorcontrib><creatorcontrib>Altamura, Haley K.</creatorcontrib><creatorcontrib>Yeoman, Alexandra L.</creatorcontrib><creatorcontrib>Georgievski, Jasmina</creatorcontrib><creatorcontrib>Jamison, Bronte A.</creatorcontrib><creatorcontrib>Phillis, Stuart</creatorcontrib><creatorcontrib>Donaldson, Zoe</creatorcontrib><creatorcontrib>Leong, Mary</creatorcontrib><creatorcontrib>Fletcher, Linda</creatorcontrib><creatorcontrib>Seymour, John F.</creatorcontrib><creatorcontrib>Grigg, Andrew P.</creatorcontrib><creatorcontrib>Ross, David M.</creatorcontrib><creatorcontrib>Hughes, Timothy P.</creatorcontrib><title>Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline</title><title>Blood</title><addtitle>Blood</addtitle><description>In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-ABL1) value >10% at 3 months of therapy is statistically associated with poorer outcome, yet many of these patients still achieve satisfactory outcomes. We investigated 528 first-line imatinib-treated patients to determine whether patients with the poorest outcome can be better discriminated at 3 months. All outcomes were significantly superior for the 410 patients with BCR-ABL1 ≤10% at 3 months (P < .001). However, the poorest outcomes among the 95 evaluable patients with BCR-ABL1 >10% at 3 months were identified by the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Patients with BCR-ABL1 halving time <76 days (n = 74) had significantly superior outcomes compared with patients whose BCR-ABL1 values did not halve by 76 days (n = 21; 4-year overall survival, 95% vs 58%, P = .0002; progression-free survival, 92% vs 63%, P = .008; failure-free survival, 59% vs 6%, P < .0001; and major molecular response, 54% vs 5%, P = .008). By multivariate analysis, the halving time was an independent predictor of outcome in this poor risk group. Our study highlighted that the rate of BCR-ABL1 decline may be a critical prognostic discriminator of the patients with very poor outcome among those >10% at 3 months. The International Randomized IFN vs STI571 (IRIS) trial was registered at http://www.clinicaltrials.gov as #NCT00006343. The Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) trial was registered at http://www.clinicaltrials.gov as #NCT00124748. The Therapeutic Intensification in DE-novo Leukaemia (TIDEL) I trial was registered at http://www.ANZCTR.org.au as #ACTRN12607000614493. The TIDEL II trial was registered at http://www.ANZCTR.org.au as #ACTRN12607000325404.
•Among patients with >10% BCR-ABL1, at 3 months, the poorest-risk group can be distinguished by the rate of BCR-ABL1 decline from baseline.•Patients with BCR-ABL1 values on a constant downward trajectory may rapidly reach the level considered optimal with additional follow-up.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fusion Proteins, bcr-abl - genetics</subject><subject>Fusion Proteins, bcr-abl - metabolism</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Piperazines - therapeutic use</subject><subject>Prognosis</subject><subject>Pyrimidines - therapeutic use</subject><subject>Remission Induction</subject><subject>Survival Rate</subject><subject>Time Factors</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rVDEUhoModlr9B1KyEdyknnzc23s3hXawHzCiiK5DbnLipNxJpklG8d-bcdouXQVOnvcc3oeQdxzOOB_Ex2lOyTEBXDGQrOt7KeQLsuCdGBiAgJdkAQA9U-M5PyLHpdxDY6XoXpMjoYZulL1akPo1p58xlVCoT5luTQ0Ya6G_Q13T5ecVNdHRCw7v6dXyG7u8WnFqfMVMJd2kWNeFJk_DpsVimKjDLUbXZpHWNdJsKu7_n6MO7RwiviGvvJkLvn18T8iP60_fl7ds9eXmbnm5YlbBUJlD7ww4mITzXJzbjrdCRngrJu5HJ0VvJwW2B-lGOyF23HK37-gnlMr08oR8OOzd5vSww1L1JhSL82wipl3RvFNDrziosaHqgNqcSsno9Ta3WvmP5qD3vvU_33rvW4PUB98tdvp4YTdt0D2HngQ34OIAYOv5K2DWxTbDFl3IaKt2Kfz_wl_f8o9q</recordid><startdate>20140724</startdate><enddate>20140724</enddate><creator>Branford, Susan</creator><creator>Yeung, David T.</creator><creator>Parker, Wendy T.</creator><creator>Roberts, Nicola D.</creator><creator>Purins, Leanne</creator><creator>Braley, Jodi A.</creator><creator>Altamura, Haley K.</creator><creator>Yeoman, Alexandra L.</creator><creator>Georgievski, Jasmina</creator><creator>Jamison, Bronte A.</creator><creator>Phillis, Stuart</creator><creator>Donaldson, Zoe</creator><creator>Leong, Mary</creator><creator>Fletcher, Linda</creator><creator>Seymour, John F.</creator><creator>Grigg, Andrew P.</creator><creator>Ross, David M.</creator><creator>Hughes, Timothy P.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140724</creationdate><title>Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline</title><author>Branford, Susan ; Yeung, David T. ; Parker, Wendy T. ; Roberts, Nicola D. ; Purins, Leanne ; Braley, Jodi A. ; Altamura, Haley K. ; Yeoman, Alexandra L. ; Georgievski, Jasmina ; Jamison, Bronte A. ; Phillis, Stuart ; Donaldson, Zoe ; Leong, Mary ; Fletcher, Linda ; Seymour, John F. ; Grigg, Andrew P. ; Ross, David M. ; Hughes, Timothy P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-defda0d0b2df127c51000a2fc2b1f9d326cb40c603d9cbee51c1d0143fbe34a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fusion Proteins, bcr-abl - genetics</topic><topic>Fusion Proteins, bcr-abl - metabolism</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Piperazines - therapeutic use</topic><topic>Prognosis</topic><topic>Pyrimidines - therapeutic use</topic><topic>Remission Induction</topic><topic>Survival Rate</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Branford, Susan</creatorcontrib><creatorcontrib>Yeung, David T.</creatorcontrib><creatorcontrib>Parker, Wendy T.</creatorcontrib><creatorcontrib>Roberts, Nicola D.</creatorcontrib><creatorcontrib>Purins, Leanne</creatorcontrib><creatorcontrib>Braley, Jodi A.</creatorcontrib><creatorcontrib>Altamura, Haley K.</creatorcontrib><creatorcontrib>Yeoman, Alexandra L.</creatorcontrib><creatorcontrib>Georgievski, Jasmina</creatorcontrib><creatorcontrib>Jamison, Bronte A.</creatorcontrib><creatorcontrib>Phillis, Stuart</creatorcontrib><creatorcontrib>Donaldson, Zoe</creatorcontrib><creatorcontrib>Leong, Mary</creatorcontrib><creatorcontrib>Fletcher, Linda</creatorcontrib><creatorcontrib>Seymour, John F.</creatorcontrib><creatorcontrib>Grigg, Andrew P.</creatorcontrib><creatorcontrib>Ross, David M.</creatorcontrib><creatorcontrib>Hughes, Timothy P.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Branford, Susan</au><au>Yeung, David T.</au><au>Parker, Wendy T.</au><au>Roberts, Nicola D.</au><au>Purins, Leanne</au><au>Braley, Jodi A.</au><au>Altamura, Haley K.</au><au>Yeoman, Alexandra L.</au><au>Georgievski, Jasmina</au><au>Jamison, Bronte A.</au><au>Phillis, Stuart</au><au>Donaldson, Zoe</au><au>Leong, Mary</au><au>Fletcher, Linda</au><au>Seymour, John F.</au><au>Grigg, Andrew P.</au><au>Ross, David M.</au><au>Hughes, Timothy P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2014-07-24</date><risdate>2014</risdate><volume>124</volume><issue>4</issue><spage>511</spage><epage>518</epage><pages>511-518</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-ABL1) value >10% at 3 months of therapy is statistically associated with poorer outcome, yet many of these patients still achieve satisfactory outcomes. We investigated 528 first-line imatinib-treated patients to determine whether patients with the poorest outcome can be better discriminated at 3 months. All outcomes were significantly superior for the 410 patients with BCR-ABL1 ≤10% at 3 months (P < .001). However, the poorest outcomes among the 95 evaluable patients with BCR-ABL1 >10% at 3 months were identified by the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Patients with BCR-ABL1 halving time <76 days (n = 74) had significantly superior outcomes compared with patients whose BCR-ABL1 values did not halve by 76 days (n = 21; 4-year overall survival, 95% vs 58%, P = .0002; progression-free survival, 92% vs 63%, P = .008; failure-free survival, 59% vs 6%, P < .0001; and major molecular response, 54% vs 5%, P = .008). By multivariate analysis, the halving time was an independent predictor of outcome in this poor risk group. Our study highlighted that the rate of BCR-ABL1 decline may be a critical prognostic discriminator of the patients with very poor outcome among those >10% at 3 months. The International Randomized IFN vs STI571 (IRIS) trial was registered at http://www.clinicaltrials.gov as #NCT00006343. The Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) trial was registered at http://www.clinicaltrials.gov as #NCT00124748. The Therapeutic Intensification in DE-novo Leukaemia (TIDEL) I trial was registered at http://www.ANZCTR.org.au as #ACTRN12607000614493. The TIDEL II trial was registered at http://www.ANZCTR.org.au as #ACTRN12607000325404.
•Among patients with >10% BCR-ABL1, at 3 months, the poorest-risk group can be distinguished by the rate of BCR-ABL1 decline from baseline.•Patients with BCR-ABL1 values on a constant downward trajectory may rapidly reach the level considered optimal with additional follow-up.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24859364</pmid><doi>10.1182/blood-2014-03-566323</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2014-07, Vol.124 (4), p.511-518 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1548641049 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - therapeutic use Benzamides - therapeutic use Female Follow-Up Studies Fusion Proteins, bcr-abl - genetics Fusion Proteins, bcr-abl - metabolism Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Male Middle Aged Piperazines - therapeutic use Prognosis Pyrimidines - therapeutic use Remission Induction Survival Rate Time Factors |
| title | Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T06%3A00%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20for%20patients%20with%20CML%20and%20%3E10%25%20BCR-ABL1%20after%203%20months%20of%20imatinib%20depends%20on%20the%20rate%20of%20BCR-ABL1%20decline&rft.jtitle=Blood&rft.au=Branford,%20Susan&rft.date=2014-07-24&rft.volume=124&rft.issue=4&rft.spage=511&rft.epage=518&rft.pages=511-518&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2014-03-566323&rft_dat=%3Cproquest_cross%3E1548641049%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1548641049&rft_id=info:pmid/24859364&rft_els_id=S0006497120399328&rfr_iscdi=true |